Tavaborole, a Novel Boron-Containing Small Molecule for the Topical Treatment of Onychomycosis, Is Noncarcinogenic in 2-Year Carcinogenicity Studies

被引：14

作者：

Ciaravino, Vic ^{[1
]}

Coronado, Dina ^{[1
]}

Lanphear, Cheryl ^{[2
]}

Shaikh, Imran ^{[3
]}

Ruddock, William ^{[3
]}

Chanda, Sanjay ^{[1
]}

机构：

[1] Anacor Pharmaceut Inc, Palo Alto, CA 94303 USA

[2] MPI Res Inc, Mattawan, MI USA

[3] ITR Labs Canada Inc, Baie Durfe, PQ, Canada

来源：

INTERNATIONAL JOURNAL OF TOXICOLOGY | 2014年 / 33卷 / 05期

关键词：

tavaborole; onychomycosis; antifungal; carcinogenicity; ANTIFUNGAL AGENT; ACIDS;

D O I：

10.1177/1091581814545245

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tavaborole, a cyclized boronic acid, has been approved by the Food and Drug Administration for the topical treatment of toenail onychomycosis. This novel, low-molecular-weight pharmaceutical compound has broad-spectrum antifungal activity against dermatophytes, yeasts, and molds responsible for the disease. Tavaborole was tested in 2-year carcinogenicity studies in mice (once daily dermal administration) and rats (once daily by oral gavage) as part of the extensive nonclinical safety program. There was no evidence of tavaborole-related neoplasms observed in either study. Based on the data gathered from these 2 carcinogenicity studies, tavaborole is considered noncarcinogenic.

引用

页码：419 / 427

页数：9

共 16 条

[11]

Peto R, 1980, IARC Monogr Eval Carcinog Risk Chem Hum Suppl, P311

[12] INHIBITION OF SERINE PROTEASES BY ARYLBORONIC ACIDS [J].